Back to Journals » Medical Devices: Evidence and Research » Volume 12

Interspinous Process Decompression With The Superion® Spacer For Lumbar Spinal Stenosis: Real-World Experience From A Device Registry

Authors Tekmyster G, Sayed D, Cairns KD, Raso LJ, Kim C, Block JE

Received 22 June 2019

Accepted for publication 20 September 2019

Published 3 October 2019 Volume 2019:12 Pages 423—427

DOI https://doi.org/10.2147/MDER.S220431

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Gene Tekmyster,1 Dawood Sayed,2 Kevin D Cairns,3 Louis J Raso,4 Christopher Kim,5 Jon E Block6

1The Orthopaedic and Sports Medicine Center, Trumbull, CT 06611, USA; 2The Center of Neuromodulation, The University of Kansas Health System, Kansas City, KS 66103, USA; 3Florida Spine Specialists, Ft. Lauderdale, FL 33308, USA; 4Jupiter Interventional Pain Management, Jupiter, FL 33477, USA; 5The Center for Pain Relief, Charleston, WV 25304, USA; 6Independent Clinical Consultant, San Francisco, CA 94115, USA

Correspondence: Jon E Block 2210 Jackson Street, Ste. 401, San Francisco, CA 94115, USA
Tel +1 415 775 7947
Email jb@drjonblock.com

Background: Interspinous process decompression (IPD) with stand-alone spacers has demonstrated excellent long-term clinical benefit for patients with lumbar spinal stenosis (LSS).
Methods: IPD used the Superion® Indirect Decompression System (Vertiflex, Carlsbad, CA, USA). Perioperative and clinical data were captured via a registry for patients treated with IPD for LSS with intermittent neurogenic claudication. Three-hundred sixteen physicians at 86 clinical sites in the US participated. Patient data were captured from in-person interviews and a phone survey. Outcomes included intraoperative blood loss, procedural time, leg and back pain severity (100 mm VAS), patient satisfaction and treatment approval at 3 weeks, 6 and 12 months.
Results: The mean age of registry patients was 73.0 ± 9.1 years of which 54% were female. Mean leg pain severity decreased from 76.6 ± 22.4 mm preoperatively to 30.4 ± 34.6 mm at 12 months, reflecting an overall 60% improvement. Corresponding responder rates were 64% (484 of 751), 72% (1,097 of 1,523) and 75% (317 of 423) at 3 weeks, 6 and 12 months, respectively. Back pain severity improved from 76.8 ± 22.2 mm preoperatively to 39.9 ± 32.3 mm at 12 months (48% improvement); 12-month responder rate of 67% (297 of 441). For patient satisfaction at 3 weeks, 6 and 12 months, 89%, 80%, and 80% were satisfied or somewhat satisfied with their treatment and 90%, 75%, and 75% would definitely or probably undergo the same treatment again. In the phone survey, the rate of revision was 3.6% (51 of 1,426).
Conclusion: These registry findings support the clinical adoption of minimally invasive IPD in patients with neurogenic claudication associated with LSS.

Keywords: Superion®, interspinous spacer, lumbar spinal stenosis, neurogenic claudication, decompression
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]